1. DOP74 Initial Clearance of infliximab is a predictor for the time of formation of anti-drug antibodies. (27th May 2021) Authors: Kutschera, M; Primas, C; Reinisch, S; Novacek, G; Kim, S H; Lee, S H; Lee, J H; Reinisch, W; Mould, D R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial. (27th May 2021) Authors: Zoller, H; Wolf, M; Blumenstein, I; Primas, C; Lindgren, S; Thomsen, L L; Reinisch, W; Iqbal, T Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P151 Risk factors for first intestinal surgery in Crohn's disease. (25th January 2019) Authors: Novacek, G; Reinisch, W; Reinisch, S; Primas, C; Eigner, W; Vogelsang, H; Dejaco, C; Kazemi-Shirazi, L; Niapir, M; Mekhail, P; Pedarnig, N; Angermann, H; Waldhör, T Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P264 Prevalence and predictors of stoma formation and restoration of intestinal continuity in patients with Crohn's disease in a tertiary referral hospital: A retrospective explorative study. (21st January 2022) Authors: Primas, C; Waldhör, T; Kozbial, K; Dawoud, C; Riss, S; Reinisch, W; Niapri, M; Kutschera, M; Kazemi-Shirazi, L; Reinisch, S; Dabsch, S; Pedarnig, N; Angermann, H; Novacek, G Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study). (27th May 2021) Authors: Bokemeyer, B; Kaiser, C; Primas, C; Novacek, G; Biedermann, L; Seibold, F; Tappe, U; Bettenworth, D; Graw, J; Hartmann, P; Plachta-Danielzik, S; Schultz, C Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P519 Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data. (27th May 2021) Authors: Hartl, C; Novacek, G; Reinisch, S; Saciri, A; Reinisch, W; Primas, C; Maier, H Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P785 A retrospective cohort study on vedolizumab trough levels in Crohn's disease patients. (30th January 2023) Authors: Pokryszka, J; Stadlmann, M; Primas, C; Gerold, N; Reinisch, S; Novacek, G; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗